---
title: "Polyrizon agrees to sell 552,269 shares at $9.00 in registered direct offering"
url: "https://aibio.space/news/polyrizon-agrees-sell-552-269-shares-9-00-registered-direct-offering/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-12-05"
section: "Listings"
tickers: "NASDAQ:PLRZ"
source: "https://www.sec.gov/Archives/edgar/data/1893645/000121390025118454/ea0268528-6k_polyrizon.htm"
summary: "Expected gross proceeds are about $4.97 million. The company says the price is a premium to the Nasdaq Minimum Price."
---

By the aibio.space news desk.

Sources

- [Polyrizon Ltd. 6-K (2025-12-05)](https://www.sec.gov/Archives/edgar/data/1893645/000121390025118454/ea0268528-6k_polyrizon.htm)

[PLRZ](https://aibio.space/companies/polyrizon/)

2025-12-05

# Polyrizon agrees to sell 552,269 shares at $9.00 in registered direct offering

Tickers [PLRZ](https://aibio.space/companies/polyrizon/)

Expected gross proceeds are about $4.97 million. The company says the price is a premium to the Nasdaq Minimum Price.

## Key facts

- **Company**: Polyrizon Ltd. (NASDAQ: PLRZ)

- **News type**: Listings

- **Primary source**: [Polyrizon Ltd. 6-K (2025-12-05)](https://www.sec.gov/Archives/edgar/data/1893645/000121390025118454/ea0268528-6k_polyrizon.htm)

*Old law books on library shelves. CC0, via rawpixel. The picture shows the field, not the companies named.*

Polyrizon Ltd. (Nasdaq: [PLRZ](https://aibio.space/companies/polyrizon/)) entered into a securities purchase agreement on December 5, 2025 to sell 552,269 ordinary shares in a registered direct offering at $9.00 per share. A registered direct offering is a sale of registered shares directly to investors.

The company said the offering price represented a premium to the Nasdaq Minimum Price under Listing Rule 5635(d). The offering is expected to close on or about December 5, 2025, subject to customary closing conditions. Aggregate gross proceeds to the company are expected to be approximately $4.97 million.

Polyrizon expects to use the net proceeds, together with its existing cash, for general corporate purposes. The company listed financing operations, capital expenditures, business development, technology development and pursuing strategic opportunities, including strategic acquisitions.

The company also agreed to pay Aegis Capital Corp a financial advisory fee of $250,000.

The shares are being issued under a prospectus supplement dated December 5, 2025, in a takedown from the company's shelf registration statement on Form F-3, which became effective on December 3, 2025. Polyrizon cautioned that the offering may not close if the conditions are not satisfied.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

PLRZ

Polyrizon Ltd.

NASDAQ · Israel

Open the starter desk

## More in Listings

Listings

### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/)

Oct 29, 2026

Listings

### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/)

Oct 29, 2026

Listings

### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/)

Oct 28, 2026

---
Source page: https://aibio.space/news/polyrizon-agrees-sell-552-269-shares-9-00-registered-direct-offering/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Polyrizon agrees to sell 552,269 shares at $9.00 in registered direct offering", 2025-12-05, https://aibio.space/news/polyrizon-agrees-sell-552-269-shares-9-00-registered-direct-offering/